OCLASSEN GLENN A 4
4 · Transcept Pharmaceuticals Inc · Filed Jan 8, 2013
Insider Transaction Report
Form 4
OCLASSEN GLENN A
DirectorPresident and CEO
Transactions
- Award
Common Stock Option (right to buy)
2013-01-07+250,000→ 250,000 totalExercise: $5.40Exp: 2023-01-07→ Common Stock (250,000 underlying)
Footnotes (1)
- [F1]The option vests in forty-eight equal monthly installments beginning on February 7, 2013.